Nano Cell Vesicles for Drug DeliveryTechnology #2017-116-nano
Questions about this technology? Ask a Technology Manager
Nano Cell Vesicles for Drug Delivery
Nano Cell Vesicle Technologies ( nCVTS) are a cell based drug delivery system that utilize the intrinsic targeting abilities of macrophages and monocytes to deliver therapeutics to tumour sites with reduced collateral damage to surrounding healthy tissues.
nCVTs are produced from the modification of macrophages and monocytes, emptying their cellular contents and rendering them into nano dimensions, while preserving the exterior protein configuration.
nCVTs can then be loaded with therapeutics, and delivered to the tumour site for its intended effect.
Additional modifications such as fluorophore labelling, click chemistry, altering the surface charges of the nanoparticles or ligand(s) addition can also be performed.
Figure 1. Protein concentration of NanoCells after passing through the spin cups. For comparison, the lipid formulation without Cell Ghosts that underwent the same procedure were used.
Figure 2. nCVTs and liposomes were labelled with a fluorescent dye and injected into a tumour mouse model. Samples were compared against the free dye. IVIS images post 24 hours showed accumulation of fluorescent labelled nCVTs and liposomes at tumour sites (orange arrows).
Figure 3. Relative fluorescence intensities of excised organs quantified by IVIS.
Improved targeting of tumour sites for therapy
Use in both in vitro & in vivo
Reduced collateral damage to surrounding healthy tissues
Highly amendable to additional functionalization
Potential dose sparing effect
A Novel Cell Based Drug Delivery System (DDS) for targeted
delivery of therapeutics.
Contact: Tristan Rouillé
Phone: +65-8120 6163
ILO Ref No: 2017-116
PIs: Ass/Prof Giorgia Pastorin & Wei Jiang Goh